Liftstream is an executive search recruitment company in the life sciences sector
PTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged Allan Jacobson, AstraZeneca, Ataluren, celgene, Cystic Fibrosis, DMD, DNA, Duchenne Muscular Dystrophy, EMA, FDA, Genzyme, Gilead, Liftstream Rare Disease Day, MAA, Marketing Authorisation Application, Merck, Orphan Drug, Pfizer, PTC Therapeutics, Rare Disease, rare disease day, RDD13, Stuart W. Peltz
Leave a comment
Funding successes allow Promethera to look to clinical data in 2013
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged Allogenic Liver Cells, Boehringer Ingelheim, clinical, Crigler-Najjar, Eric Halioua, Etienne Sokal, funding, GMP, HepStem, Liftstream, Liftstream Rare Disease Day, Liver Fibrosis, Phenylketonuria, Promethera Bioscience, rare disease day, RDD13, regenerative medicine, Shire, Stem Cells
1 Comment
Ultragenyx focused on ultra-rare disease future
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged 2013, Baylor Research Institute, BioMarin, biotech, Emil Kakkis, Fatty Acid Oxidisation Disorders, funding, Genzyme, Heriditary Inclusion Body Myopathy, IPO, Liftstream, Rare Disease, rare disease day, Sanofi, Series B, Shire, Sialic Acid, Sly Syndrome, Sudden Infant Death Syndrome, triheptanoin, ultra-rare, Ultragenyx
Leave a comment
Oxyrane seeking to advance Pompe Disease programme in 2013
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged august, Dr Charles Richard, EMA, FDA, Forbion Capital, funding, James Weston, Liftstream, LSDs, LSLraredisease, Lysosomal Storage Disorders, OXY2098-95, Oxyrane, Philip Astley-Sparke, Rare Disease, rare disease day, rare diseases, RDD13, Series D, Susan Flint, USA
Leave a comment
40 Days Until Rare Disease Day!
Authored by James Sheppard